for the maintenance treatment of copd

dual bronchodilation,

down to a science

Not indicated for the relief of acute bronchospasm or for the treatment of asthma.

Adverse reactions with BEVESPI AEROSPHERE with a ≥2% incidence and more common than placebo were urinary tract infection and cough.1

  • Intelligent formulation for a pMDI using patented CO-SUSPENSION™ Delivery Technology1
  • Designed to deliver drug crystals to the airways1,2

Improved lung function vs placebo including1

  • 150-mL improvement in predose FEV1 at 24 weeks
  • Nearly a 300-mL improvement in peak FEV1 at 24 weeks

In a separate study vs placebo

  • Achieved a 381-mL improvement vs placebo in peak inspiratory capacity on Day 293‡

*BEVESPI AEROSPHERE is a pMDI containing the LAMA glycopyrrolate and LABA formoterol fumarate, along with phospholipid porous particles that form the co-suspension with the micronized drug crystals.1

Defined as superior improvements in lung function relative to its individual components and placebo in two 24-week pivotal trials (n=3699).1,4

Results from a separate Phase IIIb trial (n=35). There was a significant mean improvement in primary endpoint FEV1 AUC0-24 on Day 29 vs placebo. Peak inspiratory capacity was a secondary endpoint.3 Similar results seen in a second Phase IIIb trial (n=75).3